Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease

BMC Neurology

Volumn 15, Issue 1, 2015, Pages

  Grolez, Guillaume ^a,b   Moreau, Caroline ^a,b   Sablonnière, Bernard ^c   Garçon, Guillaume ^d   Devedjian, Jean Christophe ^a,b   Meguig, Sayah ^a   Gelé, Patrick ^c   Delmaire, Christine ^b,c   Bordet, Regis ^a,b   Defebvre, Luc ^a,b   Cabantchik, Ioav Z ^e   Devos, David ^a,b,d  

^a UNIV LILLE   (France)

^b CHU Lille   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UFR3S Pharmacie   (France)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Deferiprone; Iron chelation; L dopa; Motor response; Parkinson's disease

Indexed keywords

CERULOPLASMIN; DEFERIPRONE; IRON; PLACEBO; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ADULT; ARTICLE; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; IRON CHELATION; MALE; MIDDLE AGED; MOTOR DYSFUNCTION; PARKINSON DISEASE; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; RANDOMIZED CONTROLLED TRIAL; SUBSTANTIA NIGRA; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; AGED; CHELATION THERAPY; CLINICAL PROTOCOL; METABOLISM; PROCEDURES; TREATMENT OUTCOME;

AGED; CERULOPLASMIN; CHELATION THERAPY; CLINICAL PROTOCOLS; FEMALE; HUMANS; IRON; IRON CHELATING AGENTS; MALE; MIDDLE AGED; PARKINSON DISEASE; PYRIDONES; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

EID: 84976601532     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-015-0331-3     Document Type: Article

References (12)

1. Breuer W, Shvartsman M, Cabantchik ZI. Intracellular labile iron. Int J Biochem Cell Biol. 2008;40:350-4.
2. Hochstrasser H, Tomiuk J, Walter U, Behnke S, Spiegel J, Krüger R, et al. Functional relevance of ceruloplasmin mutations in Parkinson's disease. FASEB J. 2005;19:1851-3.
3. Olivieri S, Conti A, Iannaccone S, Cannistraci CV, Campanella A, Barbariga M, et al. Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention. J Neurosci. 2011;31:18568-77.
4. Ayton S, Lei P, Duce JA, Wong BX, Sedjahtera A, Adlard PA, et al. Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Ann Neurol. 2013;73:554-9.
5. Boll MC, Sotelo J, Otero E, Alcaraz-Zubeldia M, Rios C. Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease. Neurosci Lett. 1999;265:155-8.
6. Hochstrasser H, Bauer P, Walter U, Behnke S, Spiegel J, Csoti I, et al. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology. 2004;63(10):1912-7.
7. Friedman A, Galazka-Friedman J. The history of the research of iron in Parkinsonian substantia nigra. J Neural Transm. 2012;119:1507-10.
8. Cabantchik ZI, Munnich A, Youdim MB, Devos D. Regional siderosis: a new challenge for iron chelation therapy. Front Pharmacol. 2013;4:167.
9. Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal. 2014;21:195-210.
10. Schosinsky KH, Lehmann HP, Beeler MF. Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin Chem. 1974;20:1556-63.
11. Martinez-Subiela S, Tecles F, Ceron JJ. Comparison of two automated spectrophotometric methods for ceruloplasmin measurement in pigs. Res Vet Sci. 2007;83:12-9.
12. Siotto M, Pasqualetti P, Marano M, Squitti R. Automation of o-dianisidine assay for ceruloplasmin activity analyses: usefulness of investigation in Wilson's disease and in hepatic encephalopathy. J Neural Transm. 2014;121:1281-6.